Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth

American Journal of Obstetrics and Gynecology

Volumn 210, Issue 2, 2014, Pages 128.e1-128.e6

  Caritis, Steve N ^a   Venkataramanan, Raman ^a   Thom, Elizabeth ^c   Harper, Margaret ^d   Klebanoff, Mark A ⁿ   Sorokin, Yoram ^e   Thorp, John M ^d   Varner, Michael W ^f   Wapner, Ronald J ^g   Iams, Jay D ^h   Carpenter, Marshall W ^j   Grobman, William A ^k   Mercer, Brian M ⁱ   Sciscione, Anthony ^b   Rouse, Dwight J ^l   Ramin, Susan ^m  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g Columbia University ^*  (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ CASE WESTERN RESERVE UNIVERSITY   (United States)

^j BROWN UNIVERSITY   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

ⁿ EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

more..

Author keywords

17 hydroxyprogesterone caproate concentration response; dose response; pharmacodynamics

Indexed keywords

HYDROXYPROGESTERONE CAPROATE; OMEGA 3 FATTY ACID; PROGESTERONE; 17-ALPHA-HYDROXY-PROGESTERONE CAPROATE; PROGESTERONE DERIVATIVE;

ARTICLE; BODY MASS; DRUG BLOOD LEVEL; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREMATURE LABOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUPPLEMENTATION; BLOOD; CONTROLLED STUDY; PREGNANCY; PREMATURE BIRTH; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SECOND TRIMESTER PREGNANCY;

FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYDROXYPROGESTERONES; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PREMATURE BIRTH; RECURRENCE;

EID: 84893683986     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2013.10.008     Document Type: Article

References (21)

1. P.J. Meis, M. Klebanoff, and E. Thom et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate N Engl J Med 348 2003 2379 2385 Erratum in: N Engl J Med 2003;349:1299 (Pubitemid 36682816)
2. American College of Obstetricians and Gynecologists ACOG committee opinion no 419: use of progesterone to reduce preterm birth Obstet Gynecol 112 2008 963 965
3. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. Center for Biologics Evaluation and Research. Guidance for industy. Exposure-response relationships-study design, data analysis, and regulatory applications. April 2013. Available at: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm072109.pdf. Accessed April 26, 2013.
4. Expert Working Group (Efficacy). International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH). Guideline for industy. Dose-response information to support drug registration. November 1994. Available at: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073115.pdf. Accessed April 26, 2013.
5. J.W. Johnson, K.L. Austin, G.S. Jones, G.H. Davis, and T.M. King Efficacy of 17α-hydroxyprogesterone caproate in the prevention of premature labor N Engl J Med 293 1975 675 690
6. M. Yemini, R. Borenstein, and E. Dreazen et al. Prevention of premature labor by 17α-hydroxyprogesterone caproate Am J Obstet Gynecol 151 1985 574 577 (Pubitemid 15049683)
7. A.L. Hartikainen-Sorri, A. Kauppila, and R. Tuimala Inefficacy of 17α-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy Obstet Gynecol 56 1980 692 695 (Pubitemid 11216937)
8. Keirse MJ NC. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynecol 1990;97:149-54.
9. K. Grasmader, P.L. Verwohlt, and K.U. Kuhn et al. Relationship between Mirtazapine dose, plasma concentration, response and side effects in clinical practice Pharmacopsychiatry 38 2005 113 117 doi: http://dx.doi.org/10.1055/s- 2005-864120 (Pubitemid 40965962)
10. P.G. Janicak, and J.M. Davis Antipsychotic dosing strategies in acute schizophrenia Intl Clin Psychopharm 11 suppl 2 1996 35 40 (Pubitemid 26194499)
11. R. Gugler, G. Fuchs, M. Dieckmann, and A. Somogyi Cimetidine plasma concentration-response relationships Clin Pharm Thera 29 1981 744 748 (Pubitemid 11006721)
12. S.N. Caritis, H.N. Simhan, and Y. Zhao et al. Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation Am J Obstet Gynecol 207 2012 396.e1 396.e8
13. S. Zhang, S.R. Mada, and S. Sharma et al. Simultaneous quantitation of 17α-hydroxyprogesterone in human plasma using high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS) J Pharamaceutical Biomed Analy 48 2008 1174 1180
14. S.N. Caritis, S. Sharma, and R. Venkataramanan et al. Pharmacology and placental transport of 17-hydroxyprogesterone caproate in a singleton gestation Am J Obstet Gynecol 207 2012 398.e1 398.e8
15. S.N. Caritis, S. Sharma, and R. Venkataramanan et al. Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation Am J Obstet Gynecol 205 2011 40.e1 40.e8
16. C. Cuppett, Y. Zhao, S.N. Caritis, S. Zhang, W. Zhao, and R. Venkataramanan Effect of endogenous steroid hormones on 17-alpha- hydroxyprogesterone caproate metabolism Am J Obstet Gynecol 208 2013 86.e1 86.e6
17. Zhao Y, Cuppett C, Caritis S, Venkataramanan R. Effect of prescription medications on 17-alpha-hydroxyprogesterone caproate (17-OHPC) metabolism. Oral presentation, abstract no. 14, at the Society for Maternal-Fetal Medicine 32nd annual meeting, Dallas, TX, February 2012.
18. M.-V. Senat, R. Porcher, and N. Winer et al. Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial Am J Obstet Gynecol 208 2013 194.e1 194.e8
19. W.A. Grobman, E.A. Thom, and C.A. Spong et al. 17 alpha- hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm Am J Obstet Gynecol 207 2012 390.e1 390.e8
20. C.P. Durnwald, C.D. Lynch, and H. Walker et al. The effect of treatment with 17 alpha-hydroxyprogesterone caproate on changes in cervical length over time Am J Obstet Gynecol 201 2009 410.e1 410.e5
21. F. Facchinetti, S. Paganelli, G. Comitini, G. Dante, and A. Volpe Cervical length changes during preterm cervical ripening: effects of 17-α-hydroxyprogesterone caproate Am J Obstet Gynecol 196 2007 453.e1 453.e4